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Model System
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ABSTRACT
Cystic fibrosis (CF) is a human genetic disorder which results in a lung environment that is highly conducive to chronic micro-
bial infection. Over the past decade, deep-sequencing studies have demonstrated that the CF lung can harbor a highly diverse
polymicrobial community. We expanded our existing in vitro model of Pseudomonas aeruginosa biofilm formation on CF-de-
rived airway cells to include this broader set of CF airway colonizers to investigate their contributions to CF lung disease, partic-
ularly as they relate to the antibiotic response of the population. Using this system, we identified an interspecies interaction be-
tween P. aeruginosa, a bacterium associated with declining lung function and worsening disease, and Streptococcus constellatus,
a bacterium correlated with the onset of pulmonary exacerbations in CF patients. The growth rate and cytotoxicity of S. constel-
latus 7155 and P. aeruginosa PA14 were unchanged when grown together as mixed biofilms in the absence of antibiotics. How-
ever, the addition of tobramycin, the frontline maintenance therapy antibiotic for individuals with CF, to a mixed biofilm of S.
constellatus 7155 and P. aeruginosa PA14 resulted in enhanced S. constellatus biofilm formation. Through a candidate genetic
approach, we showed that P. aeruginosa rhamnolipids were reduced upon tobramycin exposure, allowing for S. constellatus
7155 biofilm enhancement, and monorhamnolipids were sufficient to reduce S. constellatus 7155 biofilm viability in the absence
of tobramycin. While the findings presented here are specific to a biofilm of S. constellatus 7155 and P. aeruginosa PA14, they
highlight the potential of polymicrobial interactions to impact antibiotic tolerance in unanticipated ways.
IMPORTANCE
Deep-sequencing studies have demonstrated that the CF lung can harbor a diverse polymicrobial community. By recapitulating
the polymicrobial communities observed in the CF lung and identifying mechanisms of interspecies interactions, we have the
potential to select the best therapy for a given bacterial community and reveal potential opportunities for novel therapeutic in-
terventions. Using an in vitro model of bacterial infection on CF airway cells, we tested how a particular polymicrobial commu-
nity grows, damages human cells, and responds to antibiotics in single and mixed infections. We describe here the mechanism of
an interspecies interaction between two pathogens in the CF lung, P. aeruginosa and S. constellatus, which is potentiated by a
commonly prescribed antibiotic, tobramycin.
Cystic fibrosis is a human genetic disease caused by mutationsin the cystic fibrosis transmembrane conductance regulator
(CFTR) gene. Mutations in the CFTR gene result in a wide array of
deleterious effects throughout the body, including chronic life-
long respiratory infections, the primary cause of morbidity and
mortality in patients with cystic fibrosis. Historically, chronic lung
infections have been attributed to relatively few organisms, in-
cluding Pseudomonas aeruginosa, Staphylococcus aureus, Haemo-
philus influenzae, and Burkholderia cepacia complex (1–3). How-
ever, deep-sequencing studies have revealed that this list of
microbes underestimates and oversimplifies the polymicrobial
communities that reside in the airways of patients with cystic fi-
brosis (CF) (4–10). Dozens of bacterial genera have been identi-
fied in a single sputum sample, including organisms not generally
identified by conventional culturing, such as Streptococcus spp.,
and anaerobes, including Prevotella (4–14).
Interspecies interactions within polymicrobial communities
can be cooperative and competitive and can be influenced by the
presence of antibiotics (15–17). Of particular interest in the CF
lung is the potential for interspecies interactions between P.
aeruginosa and Streptococcus species. P. aeruginosa is the most
abundant and prevalent organism identified by deep-sequencing
and culture-based methods in sputum samples from adult CF
patients (4–10, 18). Colonization by P. aeruginosa is associated
with worsening lung function and disease progression (1–3) and
thus has received the most attention in studies of microbial patho-
genesis in the CF lung.
Interestingly, several recent deep-sequencing studies identified
Streptococcus spp. as among the top three most abundant and
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prevalent organisms in CF sputum, and in a study from our group,
Streptococcus spp. were the predominant organisms in the sputum
of 50% of the patients at our CF center (4, 6, 9). Despite the high
abundance and prevalence of Streptococcus spp. in CF sputum, the
role that Streptococcus spp. play in disease is unclear. In a cross-
sectional study, infection with Streptococcus was reported to be
associated with better health (6). However, Sibley et al. (11, 12)
and Parkins et al. (19) reported that high numbers of Streptococcus
milleri group organisms (S. anginosus, S. constellatus, and S. inter-
medius) in sputum samples are correlated with the onset of pul-
monary exacerbation (11, 12, 19). The S. milleri group can be
identified in the sputum samples from comparatively healthy (sta-
ble) CF patients (6); therefore, the simple presence or absence of a
given microbe does not accurately predict the virulence of a com-
munity. Thus, identifying potential pathogenic and/or health-
promoting bacterial interactions within the CF sputum commu-
nity requires more information than survey studies provide.
Here, we sought to analyze how the composition of a bacterial
community contributes to its physiology, pathogenesis, and anti-
biotic response in a mixed-culture model of cystic fibrosis. Given
the studies showing that the S. milleri group is associated with the
onset of pulmonary exacerbations, we hypothesized that a mixed
community of P. aeruginosa and members of the S. milleri group
would exhibit increased virulence or increased antibiotic toler-
ance compared to that with each bacterium alone. To this end, we
expanded our previously described coculture system of P. aerugi-
nosa biofilm formation on the surface of CF airway cells (20–22) to
include the S. milleri group and other microbes identified by deep
sequencing as being highly abundant and prevalent. In addition,
we examined mixed communities of S. milleri group organisms
and P. aeruginosa and their responses to antibiotic exposure. With
this expanded system, we identified and characterized one exam-
ple of interspecies interaction between P. aeruginosa PA14 and S.
constellatus 7155 when treated with the commonly prescribed an-
tibiotic tobramycin.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The P. aeruginosa strains used
in this study are listed in Table S1 in the supplemental material and were
grown on LB agar or liquid supplemented with 25 g/ml gentamicin, 100
g/ml carbenicillin, and where appropriate, shaking at 37°C. S. constella-
tus 7155 was grown on blood agar and Todd-Hewitt broth supplemented
with 0.5% yeast extract (THY) and 20 l/ml Oxyrase (Oxyrase, Inc.) un-
der static conditions at 37°C in a 5% CO2 atmosphere. For mixed-culture
assays, P. aeruginosa was selected on Pseudomonas isolation agar at 37°C,
and S. constellatus was enriched on tryptic soy agar (TSA) supplemented
with 5% defibrinated sheep’s blood (blood agar) and grown anaerobically
in GasPak Jars at 37°C. Information relevant to the growth of the other
microbes mentioned in the manuscript is detailed in the supplemental
material.
Tissue culture cultivation. The cystic fibrosis bronchial epithelial
(CFBE) cell line used in this study overexpresses F508del-cystic fibrosis
transmembrane conductance regulator (CFTR) via stable lentiviral trans-
fection of human bronchial epithelial cells (23). The parent cell line,
named CFBE41o, was isolated from a CF patient who was homozygous
for the F508del-CFTR mutation and was originally characterized by Br-
uscia and colleagues (24) and Cozens et al. (25). CFBE cells, here referred
to as CF airway cells, were the generous gift of J. P. Clancy. CF airway cells
were cultivated as previously described (20, 22). Briefly, CF airway cells
were seeded into 24-well plates at 50,000 cells/well and fed every other day
with minimal essential medium (MEM) (Life Technologies) supple-
mented with 2 mM L-glutamine, 50 U/ml penicillin, 50 g/ml streptomy-
cin, 2 g/ml puromycin, 5 g/ml Plasmocin (InvivoGen), and 10% fetal
bovine serum until confluent and tight junctions had formed (5 to 7 days).
Growth kinetics of biofilms formed on CF airway cells. Assays of
biofilms formed on CF airway cells were performed as previously de-
scribed (20–22), with the following modifications. An overnight culture of
P. aeruginosa or S. constellatus was washed and resuspended in 1 ml of
MEM. A P. aeruginosa inoculum was prepared to an optical density at 600
nm (OD600) of 0.05 (5  10
7 CFU/ml), and an S. constellatus inoculum
was prepared to an OD600 of 0.1 (5  10
7 CFU/ml), both in MEM
supplemented with 2 mM L-glutamine. A 1:1 mixture of P. aeruginosa and
S. constellatus was prepared from these suspensions. Half a milliliter of
each suspension (P. aeruginosa alone, S. constellatus alone, and a 1:1 mix-
ture) was then gently added to each well of CF airway cells that had been
washed twice with MEM. The cocultures were incubated 1 h at 37°C in 5%
CO2. At 1 h, unattached bacteria were removed by aspiration and the
medium replaced with MEM supplemented with 2 mM L-glutamine and
0.4% arginine. Biofilms were allowed to incubate for a total of 1, 3, or 6 h.
At each time point, planktonic cells were removed by aspiration, and the
remaining biofilms were washed once with MEM supplemented with 2
mM L-glutamine and 0.4% arginine. Fresh MEM supplemented with 2
mM L-glutamine and 0.4% arginine was added to the wells before scraping
biofilms with a pipette tip. Biofilm-grown bacteria were serially diluted
and plated on Pseudomonas isolation agar (PIA) and blood agar, as de-
scribed above, to identify P. aeruginosa and Streptococcus spp., respec-
tively. PIA was incubated overnight at 37°C, and blood agar was incubated
overnight anaerobically in GasPak jars at 37°C. After overnight incuba-
tion, the resulting colonies were counted and the CFU determined.
Biofilm antibiotic assay. Coculture biofilm assays were performed as
previously described (20), with the following modifications. The cocul-
ture assays were inoculated as described above in the growth kinetic as-
says. One hour postinoculation, unattached cells were removed by aspi-
ration and the medium replaced with MEM supplemented with 2 mM
L-glutamine and 0.4% arginine. Six hours postinoculation, the unattached
bacteria were removed by aspiration; the biofilm fraction was washed
once with MEM supplemented with 2 mM L-glutamine and 0.4% arginine
and then incubated with or without 5 g/ml tobramycin in MEM supple-
mented with 2 mM L-glutamine and 0.4% arginine. Twenty-one hours
postinoculation, planktonic fractions were removed and saved for use in a
drop collapse assay. MEM supplemented with 2 mM L-glutamine and
0.4% arginine was added to the wells, and biofilms were disrupted by
scraping with a pipette tip. The biofilm-grown bacteria were serially di-
luted and then plated on PIA and blood agar to distinguish the microbes,
as described above. PIA was incubated overnight at 37°C, and blood agar
was incubated anaerobically overnight at 37°C in GasPak jars. After over-
night incubation, the resulting colonies were counted and the CFU deter-
mined. Antibiotic assays on plastic were performed exactly as on CF
airway cells, except biofilms were formed directly on plastic tissue culture-
treated 24-well plates. When indicated, rhamnolipids (50 g/ml, dis-
solved in MEM; Sigma) were added to washed preformed biofilms at 6 h
postinoculation. When indicated, heat-killed wild-type P. aeruginosa cells
were added to the washed preformed biofilms at 6 h postinoculation.
Heat-killed P. aeruginosa was prepared from an overnight culture grown
in LB that was washed once and resuspended in 1 ml of MEM. The OD600
was calculated for this suspension, and an appropriate volume of cells was
heat killed at 80°C for 10 min. The heat-killed bacteria were then resus-
pended in MEM supplemented with 2 mM L-glutamine and 0.4% arginine
with or without tobramycin and added to the washed preformed biofilms.
Microscopy. MatTek dishes were seeded with 200,000 CF airway cells/
dish and grown until tight junctions formed (5 to 7 days), as described
previously (20–22). P. aeruginosa PA14 harboring a constitutively ex-
pressed gfp gene (26) and S. constellatus 7155 were prepared as described
for the coculture assays and added to twice-washed CF airway cells. Un-
attached bacteria were removed after 1 h, and the medium was replaced
with MEM supplemented with 2 mM L-glutamine and 0.4% arginine. At 3
and 4 h postinoculation, the unattached bacteria were removed, and the
Price et al.
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medium was replaced with MEM supplemented with 2 mM L-glutamine,
0.4% arginine, and 2.5 l of a 3.125% hexidium iodine solution (which
selectively stains Gram-positive bacteria red to stain S. constellatus) and
incubated for 15 min at 37°C in 5% CO2. Single-strain and mixed biofilms
were visualized on a Nikon Eclipse Ti inverted microscope with a 100
objective, and images were acquired using the Nikon ND acquisition soft-
ware and a Hamamatsu C11440 Orca-Flash 4.0 digital camera. P. aerugi-
nosa was visualized via its green fluorescence with the green fluorescent
protein (GFP) channel of the ND acquisition software; S. constellatus was
visualized via its red fluorescence in the mCherry channel of the ND
acquisition software.
Drop collapse assay. Drop collapse assays were performed as previ-
ously described (27, 28). Briefly, planktonic fractions from biofilm assays
were collected and clarified by centrifugation. The clarified supernatants
were serially diluted (1:1) with water in a 96-well plate. Thirty microliters
of each dilution was spotted onto the circles on the underside of the lid of
the 96-well plate and assessed for surfactant activity, as measured by the
spread of the droplet. As surfactant quantities are reduced by dilution,
surface tension increases, resulting in the beading up of the droplet. Sur-
factant scores are equal to the reciprocal of the greatest dilution at which
there was surfactant activity (a collapsed drop). A score of 1 is assigned to
surfactant activity in the undiluted supernatant of the wild-type strain.
Cytotoxicity assays. Cytotoxicity was measured as fraction of lactate
dehydrogenase (LDH) release compared to total lysis control of unin-
fected CF airway cells treated with Triton X-100 detergent to completely
lyse cells and release all intracellular LDH using the Cyto Tox 96 nonra-
dioactive cytotoxicity kit (Promega), according to the manufacturer’s in-
structions.
RESULTS
Expanded model system of bacterial biofilm formation on CF
airway cells. Our existing model system of bacterial biofilm for-
mation on the surface of CF-derived bronchial epithelial (CFBE)
cells was originally designed to study P. aeruginosa biofilms. P.
aeruginosa grown in this model system recapitulates several key
aspects of chronic biofilm formation, including the formation of
biofilm-like microcolonies, expression of genes associated with
biofilm growth, induction of quorum sensing, requirement for
genes necessary for biofilm formation on abiotic surfaces, and, of
importance in the clinic, increased antibiotic tolerance (20, 22).
We expanded this system to assess the biofilm-forming ability of
seven Streptococcus species and other microbes identified by deep-
sequencing studies as highly abundant and/or prevalent in spu-
tum from CF patients, including Prevotella intermedia, S. aureus,
Fusobacterium nucleatum, Stenotrophomonas maltophilia, and Ge-
mella species (4–6, 9). Each species was inoculated individually
onto CF airway cells for a total of 1, 3, or 6 h and assessed for
bacterial viability. Fifteen of the 16 species tested were able to grow
on the surface of CF airway cells (see Fig. S1A in the supplemental
material). We were unable to recover viable bacteria from obligate
anaerobe F. nucleatum cultures on CF airway cells, likely because
our culturing conditions were not anoxic (see Fig. S1A).
Given that P. aeruginosa and S. milleri group organisms may
influence the overall pathogenesis in the CF lung (1–3, 6, 11, 12,
14, 19), we sought to assess whether P. aeruginosa and Streptococ-
cus interactions might impact cell growth or cytotoxicity to host
cells. Pairwise combinations of P. aeruginosa and S. milleri group
organisms were grown as biofilms on CF airway cells, assayed for
their cytotoxicity and bacterial growth kinetics, and compared
with respect to their single-species cytotoxicity and growth kinet-
ics. S. milleri group and P. aeruginosa mixed biofilms on CF airway
cells showed a level of cytotoxicity after 1 and 3 h of biofilm for-
mation similar to that seen with single P. aeruginosa biofilms. At 6
h, the two strains of S. constellatus showed similar levels of cyto-
toxicity toward host cells, while S. anginosus and S. intermedius
showed reduced levels of cytotoxicity toward host cells compared
to those with single P. aeruginosa biofilms formed on CF airway
cells (see Fig. S1B in the supplemental material). P. aeruginosa
growth was largely unaffected by growth in the presence of the
four streptococcal strains tested (Fig. 1A; see also Fig. S1C in the
supplemental material). We did observe a modest but significant
reduction of P. aeruginosa growth at 6 h (t test, P  0.05) when this
microbe was cocultured with S. constellatus 7155 (Fig. 1A), but no
difference in CFU was observed by 24 h. While coculture with P.
aeruginosa did not impact the growth of S. constellatus 7155 (Fig.
1B), S. constellatus C818, or S. anginosus, we did notice a signifi-
cant impact of growth on a coculture of S. intermedius with P.
aeruginosa, as described in Fig. S1D to F in the supplemental ma-
terial.
Tobramycin treatment enhances growth of S. constellatus
7155 in a mixed biofilm with P. aeruginosa. Individuals with CF
receive aerosolized antibiotics on a regular basis as part of a main-
tenance therapy regimen and intravenous antibiotics upon admis-
sion to the hospital during a pulmonary exacerbation. We there-
fore hypothesized that antibiotic treatment would affect the
physiology and/or pathogenesis of P. aeruginosa or the S. milleri
group in mixed biofilms. To test this idea, we established single
and mixed biofilms of P. aeruginosa and S. constellatus, S. angino-
sus, or S. intermedius for 6 h on CF airway cells before treating the
FIG 1 Growth kinetics of P. aeruginosa and S. constellatus in CF airway cells.
(A) P. aeruginosa growth kinetics are largely unaffected by the presence of S.
constellatus 7155. The dashed line indicates the viability of P. aeruginosa grown
as single biofilms on CF airway cells, and the solid line indicates the viability of
P. aeruginosa grown as mixed biofilms on CF airway cells with S. constellatus
7155. The only significant difference was noted at 6 h, with no significant
difference at 24 h. *, P  0.05. (B) S. constellatus 7155 growth kinetics are
unaffected by the presence of P. aeruginosa PA14. The dashed line indicates
viability of S. constellatus 7155 grown as single biofilms on CF airway cells, and
the solid line indicates viability of S. constellatus 7155 grown as mixed biofilms
on CF airway cells with P. aeruginosa. For all panels, the symbols and error bars
indicate the means and standard deviations (SD) of the results from three
biological replicates.
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established biofilms with 5 g/ml tobramycin or growth medium
as a control, as previously reported (20–22). After 15 h of antibi-
otic treatment, bacterial biofilm viability (measured as the num-
ber of CFU per well) was determined for the mixed community
and compared to the bacterial biofilm viability for each organism
grown individually under the same conditions.
Viable P. aeruginosa levels decreased 200-fold when P.
aeruginosa was treated with 5 g/ml tobramycin and grown alone
or in mixed biofilms with S. constellatus 7155 (Fig. 2A). S. constel-
latus 7155 grown alone on CF airway cells showed a 2.5-fold de-
cline in viability when treated with 5 g/ml tobramycin. A mixed
biofilm of S. constellatus 7155 and P. aeruginosa in the absence of
tobramycin resulted in a nonsignificant trend toward enhanced S.
constellatus 7155 viability similar to that seen with single S. con-
stellatus 7155 biofilms after 21 h of growth. However, when mixed
biofilms of S. constellatus 7155 and P. aeruginosa were treated with
tobramycin, the viability of S. constellatus 7155 statistically signif-
icantly increased 6-fold compared to that of the mixed commu-
nity without tobramycin and 292-fold compared to that of single
S. constellatus 7155 biofilms in the presence of this antibiotic (Fig.
2A). Thus, the presence of P. aeruginosa PA14 may be beneficial
for S. constellatus 7155 when this microbe is grown in biofilms on
CF airway cells, and S. constellatus 7155 clearly benefits when the
community is treated with tobramycin. Interestingly, we saw no
differences in single and mixed cultures with or without tobramy-
cin when we examined the planktonic population (Fig. 2B) or
cytotoxicity (Fig. 2C).
The coculture of S. constellatus 7155 with P. aeruginosa PAO1
did not show a significant enhancement in S. constellatus 7155
growth in the presence or absence of tobramycin (see Fig. S2A in
the supplemental material). We also found no evidence of a tobra-
mycin-dependent interaction with P. aeruginosa PA14 when
tested with two other members of the S. milleri group, S. interme-
dius and S. anginosus, or with S. constellatus C818 (see Fig. S2B in
the supplemental material), indicating that the observed pheno-
type was specific for this strain of S. constellatus (see Discussion).
Characterization of tobramycin-dependent enhancement of
S. constellatus 7155 in mixed biofilms with P. aeruginosa PA14.
One explanation for the increase in S. constellatus 7155 CFU in
mixed biofilm with P. aeruginosa treated with tobramycin may be
enhanced nutrient availability. That is, tobramycin reduced viable
P. aeruginosa levels in this assay by 256-fold; it is possible that these
dead P. aeruginosa serve as a source of nutrients for S. constellatus
7155, thus allowing for their increased viability. To address this
possibility, heat-killed P. aeruginosa was added to single S. constel-
latus 7155 biofilms grown on CF airway cells at the same time as
the addition of antibiotic to mimic the availability of nutrients
from dying P. aeruginosa. S. constellatus 7155 biofilms that re-
ceived heat-killed P. aeruginosa had significantly lower viable
counts than those of S. constellatus 7155 grown as mixed biofilms
with live P. aeruginosa (Fig. 3A). Additionally, the viability of S.
constellatus 7155 that received heat-killed P. aeruginosa did not
increase upon tobramycin treatment (Fig. 3A).
We next examined P. aeruginosa PA14 and S. constellatus 7155
growing as biofilms on CF airway cells via epifluorescence micros-
copy. We reasoned that understanding the physical proximity of
S. constellatus 7155 and P. aeruginosa in mixed biofilms on CF
airway cells would be informative in understanding the mecha-
nism of this interspecies interaction. In these studies, P. aeruginosa
PA14 was visualized by its green fluorescence from a GFP consti-
tutively expressed from a plasmid (26), while S. constellatus 7155
was visualized by its red fluorescence after staining with hexidium
iodide, which preferentially stains Gram-positive bacteria (Fig. 3C
and D) (29). When examined by phase contrast and fluorescence
microscopy, P. aeruginosa and S. constellatus 7155 were found to
colocalize on the surface of CF airway cells in vitro (Fig. 3B). Co-
localization was not required for biofilm formation, as single-spe-
cies biofilms of P. aeruginosa or S. constellatus 7155 were also vi-
sualized in mixed biofilms (Fig. 3B) and single-species biofilms
(Fig. 3C and D).
To determine if the impact of tobramycin on S. constellatus
7155 when grown in mixed biofilms with P. aeruginosa on CF
FIG 2 Tobramycin (Tob) treatment of P. aeruginosa and S. constellatus mixed
biofilms enhances S. constellatus viability. The data represent the viability of
bacteria grown as biofilms at 21 h on CF airway cells from assays of single or
mixed biofilms of P. aeruginosa and S. constellatus 7155 treated with no tobra-
mycin or with 5 g/ml tobramycin. (A) Viability of bacteria in the biofilm
fraction. (B) Viability of bacteria in the planktonic fraction. (C) Cytotoxicity of
indicated mixed biofilms on CF airway cells. Cytotoxicity was normalized to
total cell lysis. *, P  0.05; **, P  0.01; ***, P  0.001, as determined by
analysis of variance (ANOVA) with Tukey’s posttest for multiple comparisons.
P.a., P. aeruginosa; S.c., S. constellatus. For all panels, the bars and error bars
indicate the means and SD of the results from three biological replicates.
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airway cells was dependent upon the presence of host cells, the
biofilm assays described above were repeated for biofilms grown
on the plastic surface of 24-well plates rather than a monolayer of
CF airway cells. Levels of P. aeruginosa grown alone or in mixed
biofilms on plastic decreased by 187-fold and 78-fold with tobra-
mycin treatment (Fig. 3E), respectively, recapitulating the find-
ings obtained from CF airway cell-grown biofilms (Fig. 2). Simi-
larly, the growth and antibiotic response of plastic-grown S.
constellatus 7155 single-species biofilms were comparable to those
observed for CF airway cell-grown S. constellatus 7155 single-spe-
cies biofilms, decreasing by 1.4-fold (Fig. 3E). In contrast, mixed
biofilms of S. constellatus 7155 and P. aeruginosa on plastic re-
sulted in a sharp 105-fold decline in the numbers of S. constellatus
7155 without tobramycin treatment compared to untreated single
S. constellatus 7155 biofilms. Interestingly, a 150-fold increase in S.
constellatus 7155 viability was observed in the presence of P.
aeruginosa during tobramycin treatment of these mixed-species
plastic-grown biofilms (Fig. 3E), a finding similar to that shown
for CF airway cell-grown biofilms (Fig. 2A).
In summary, we demonstrated that heat-killed P. aeruginosa
cannot recapitulate the tobramycin-dependent enhancement of S.
constellatus 7155 growth in mixed biofilms with P. aeruginosa and
that S. constellatus 7155 colocalizes with P. aeruginosa on CF air-
way cells. Studies of biofilms grown on plastic indicate that P.
aeruginosa inhibited the growth of S. constellatus 7155 on plastic,
but this inhibition could be relieved by the addition of tobramy-
cin. The growth of biofilms on CF airway cells is somewhat more
complex. In the absence of tobramycin, S. constellatus 7155 shows
a stimulation of growth in the presence of P. aeruginosa which is
further enhanced upon treatment with tobramycin, indicating a
potential multifactorial interaction between these two microbes
when grown on CF airway cells. In the subsequent studies de-
scribed below, we focus on the ability of tobramycin to enhance
the population of S. constellatus 7155 when this microbe is grown
in the presence of P. aeruginosa PA14, thereby allowing us to per-
form our assays on plastic or on CFBE cells.
Screening for P. aeruginosa genes responsible for tobramy-
cin-dependent S. constellatus biofilm growth enhancement us-
ing a candidate gene approach. We hypothesized that the increase
in S. constellatus 7155 biofilm viability when treated with tobra-
mycin in mixed biofilms with P. aeruginosa PA14 was due to a
tobramycin-dependent change in gene expression by P. aerugi-
nosa, consistent with several studies demonstrating that P. aerugi-
nosa gene expression changes in response to tobramycin treat-
ment (20, 30–36). Specifically, we hypothesized that tobramycin
treatment activates one or more P. aeruginosa genes that enhance
FIG 3 Characterization of tobramycin enhancement of S. constellatus in mixed biofilms with P. aeruginosa. (A) Viability of S. constellatus 7155 grown as biofilms
on CF airway cells from assays of single or mixed biofilms of heat-killed P. aeruginosa PA14 or non-heat-killed P. aeruginosa PA14, as indicated, treated with no
tobramycin or with 5 g/ml tobramycin. ****, P  0.0001, as determined by ANOVA, with Tukey’s posttest for multiple comparisons. WT, wild type. (B) P.
aeruginosa and S. constellatus colocalize in vitro. Shown is a representative image of a mixed-species biofilm of P. aeruginosa (green, expressing GFP) and S.
constellatus 7155 (red, stained with hexidium iodide) on the surface of CF airway cells (gray) at 3 h postinoculation with P. aeruginosa and S. constellatus 7155.
(C) Representative image of a single-species biofilm of P. aeruginosa (green, expressing GFP) on the surface of CF airway cells (gray) at 3 h postinoculation with
P. aeruginosa alone. Red staining indicates the nonspecific staining levels of hexidium iodide for CF airway cells. (D) Representative image of S. constellatus 7155
(red, stained with hexidium iodide) on the surface of CF airway cells (gray) at 3 h postinoculation with S. constellatus 7155 alone. (E) Tobramycin treatment
of P. aeruginosa and S. constellatus 7155 mixed biofilms enhances S. constellatus biofilm formation on plastic. The data represent the viability of bacteria grown
as biofilms on plastic from biofilm assays on single or mixed biofilms of P. aeruginosa and S. constellatus 7155 treated with no tobramycin or 5 g/ml tobramycin.
*, P  0.05; ***, P  0.001, as determined by the Mann-Whitney test. For panels A and E, the bars and error bars indicate the means and SD of the results from
three biological replicates.
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S. constellatus 7155 biofilm viability, or alternatively, that tobra-
mycin treatment could repress one or more P. aeruginosa genes
that diminish S. constellatus 7155 biofilm viability. From a list of
candidate genes chosen for their reported change in expression in
response to tobramycin treatment, role in biofilm formation,
and/or antibiotic tolerance (see Table S2 in the supplemental ma-
terial), we performed a screen with mutant P. aeruginosa PA14
strains and wild-type S. constellatus 7155 to identify P. aeruginosa
genes responsible for enhancing S. constellatus 7155 survival in
mixed biofilms on plastic when treated with tobramycin. We per-
formed the first round of this screen on plastic because growth on
plastic served as a facile experimental tool, as this assay allowed us
to focus on the P. aeruginosa-mediated growth inhibition of S.
constellatus 7155 and the relief of that inhibition upon treatment
with tobramycin. Forty-three mutant P. aeruginosa strains were
tested in the screen with wild-type S. constellatus 7155 grown as
biofilms on plastic (see Table S2); a mixture of the wild-type P.
aeruginosa with wild-type S. constellatus 7155 served as the con-
trol.
Several genes related to rhamnolipid production were identi-
fied as candidates for mutations capable of enhancing S. constella-
tus 7155 growth in the absence of tobramycin treatment; that is,
the viable counts of S. constellatus 7155 were equally high with or
without tobramycin when cultured with P. aeruginosa strains car-
rying these mutations on plastic. Rhamnolipids are produced by
the rhlA, rhlB, and rhlC gene products, which are responsible for
the biosynthesis of -hydroxyalkanoyl–-hydroxyalkanoic acids
(HAAs), monorhamnolipids, and dirhamnolipids, respectively,
all of which are surfactants secreted by P. aeruginosa (Fig. 4A). The
rhlA and rhlB genes are organized in an operon and transcription-
ally induced by the activated quorum-sensing regulator RhlR. The
rhlC gene is located elsewhere on the chromosome and is also
activated by RhlR (27, 37–40).
Mixed biofilms of S. constellatus 7155 with P. aeruginosa PA14
strains carrying mutations in the rhlA or rhlB genes resulted in
high S. constellatus 7155 viability without the addition of tobra-
mycin on plastic (Fig. 4B), a phenotype suggesting that tobramy-
cin repressed the production of HAAs and monorhamnolipids.
Consistent with this finding, mixed biofilms of S. constellatus 7155
and P. aeruginosa PA14 mutants with defects in the transcriptional
activators of rhlA and rhlB (the lasR, rhlR, and lasR rhlR mutants)
also resulted in high S. constellatus 7155 biofilm viability without
the addition of tobramycin (see Table S2 in the supplemental ma-
terial). Mixed biofilms of S. constellatus 7155 and a P. aeruginosa
PA14 strain carrying a mutation in the rhlC gene did not result in
an increase in the level of S. constellatus 7155 without the addition
of tobramycin (Fig. 4B), phenocopying mixed biofilms of S. con-
stellatus 7155 and wild-type P. aeruginosa PA14. This result sug-
gested that HAAs and/or monorhamnolipids produced by the
rhlC P. aeruginosa strain were sufficient to repress S. constellatus
7155.
To address whether tobramycin did indeed reduce the produc-
tion of surfactants by P. aeruginosa, bulk surfactant production
was measured by a drop collapse assay, as previously described
(27, 28), to measure the effect of tobramycin on surfactant secre-
tion into the supernatant. In a representative assay, mixed bio-
films of S. constellatus 7155 and wild-type P. aeruginosa PA14 re-
sulted in a surfactant score of 1.0 without tobramycin treatment
and results below the limit of detection with tobramycin treat-
ment (Fig. 4C). Mixed biofilms of S. constellatus 7155 and the P.
aeruginosa PA14 rhlA mutant or the rhlB mutant resulted in a
surfactant score of 0.5 with and without tobramycin treatment
(Fig. 4C). A mixed biofilm of S. constellatus 7155 and the P. aerugi-
nosa PA14 rhlC mutant showed surfactant scores of 1.0 without
tobramycin treatment and 0.5 with tobramycin treatment (Fig.
4C). These results suggested that tobramycin interferes with rh-
amnolipid production and that the surfactants produced by the P.
aeruginosa PA14 rhlC mutant are sufficient to inhibit S. constella-
tus 7155 biofilms. Thus, we propose that rhamnolipids negatively
impact S. constellatus 7155 viability in a biofilm formed on plastic,
monorhamnolipids are sufficient for this effect, and the loss of
rhamnolipid production by P. aeruginosa PA14 upon tobramycin
treatment allows for the increased S. constellatus 7155 observed in
our study.
P. aeruginosa-produced monorhamnolipids inhibit S. con-
stellatus biofilms on airway cells. We next asked if rhamnolipids
reduced S. constellatus 7155 CFU in mixed biofilms with P. aerugi-
nosa PA14 formed on the more clinically relevant CF airway cells.
Mixed biofilms of S. constellatus 7155 and the P. aeruginosa PA14
strains with mutations in the rhlA or rhlB genes formed on airway
cells resulted in a level of S. constellatus 7155 viability without
FIG 4 Monorhamnolipids prevent S. constellatus biofilm formation in mixed
biofilms with P. aeruginosa on plastic. (A) Diagram of rhamnolipid biosyn-
thetic pathway and the proteins required for each step in the biochemical
pathway. Mutating rhlA would result in an accumulation of hydroxyacyl-ACP
(HA), mutating rhlB results in the accumulation of -hydroxyalkanoyl–-
hydroxyalkanoic acid (HAA), and the loss of rhlC causes the accumulation of
monorhamnolipids (mono). di, dirhamnolipid. (B) Viability of S. constellatus
7155 grown as mixed biofilms on plastic from biofilm assays of S. constellatus
7155 with the wild type or the rhlA, rhlB, or rhlC mutant of P. aeruginosa, not
treated with tobramycin or treated with 5 g/ml tobramycin. The bars and
error bars indicate the means and SD of the results from three biological rep-
licates. ***, P  0.001; *, P  0.05, as determined by the Mann-Whitney test.
(C) Representative surfactant score from assays of mixed biofilms of S. constel-
latus 7155 with the wild type or the rhlA, rhlB, or rhlC mutant of P. aeruginosa
on plastic, not treated with tobramycin or treated with 5 g/ml tobramycin.
The dashed line indicates the limit of detection.
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tobramycin (Fig. 5A) which is typically observed for this organism
only when grown in the presence of P. aeruginosa PA14 with to-
bramycin. Mixed biofilms of S. constellatus 7155 and the P. aerugi-
nosa PA14 rhlC mutant formed on airway cells did not result in
increased S. constellatus 7155 CFU without tobramycin (Fig. 5A).
Similar to what we observed on plastic, when grown as mixed
biofilms on airway cells, S. constellatus 7155 CFU were the highest
in mixed biofilms in which surfactant levels were the lowest (Fig.
5A and B). These results suggest that the surfactants produced by
the P. aeruginosa rhlC mutant are sufficient to repress S. constella-
tus 7155 growth on airway cells.
It is possible that the tobramycin-dependent increase in S. con-
stellatus 7155 viability in mixed biofilms formed on airway cells
was due to an increased opportunity to colonize and/or additional
nutrients that were available due to the reduced population of P.
aeruginosa in the tobramycin-treated mixed biofilm. Several lines
of evidence argue against this idea. First, single S. constellatus 7155
biofilms grown on CF airway cells, which should have the most
available colonization surface and nutrients, have smaller
amounts of viable S. constellatus 7155 than mixed biofilms of S.
constellatus 7155 and P. aeruginosa (Fig. 2A). Second, adding heat-
killed P. aeruginosa to an S. constellatus 7155 biofilm grown on CF
airway cells did not result in increased S. constellatus 7155 viability
(Fig. 3A). Third, the rhlA mutant used in these studies harbors a
gentamicin resistance cassette in place of the rhlA gene, conferring
cross-resistance to tobramycin to this mutant. In mixed biofilms
of S. constellatus 7155 and the P. aeruginosa rhlA mutant, there are
high levels of S. constellatus 7155 and P. aeruginosa with and with-
out the addition of tobramycin (Fig. 5A and C). These results
suggest that the growth enhancement of S. constellatus 7155 is not
promoted by the absence of P. aeruginosa. Instead, these genetic
studies support the model that P. aeruginosa-secreted rhamnolip-
ids inhibit S. constellatus 7155 biofilm formed on CF airway cells
and that surfactant production can be repressed by the addition of
tobramycin.
Exogenous rhamnolipids inhibit S. constellatus biofilm for-
mation on airway cells. We further confirmed the role of rham-
nolipids in reducing S. constellatus viability by adding purified
commercially available rhamnolipids (a mixture of mono- and
dirhamnolipids) to a mixed biofilm of S. constellatus 7155 and the
P. aeruginosa rhlA mutant. Rhamnolipids were added at 50 g/ml,
a concentration that has been measured in broth-grown P. aerugi-
nosa (41). The addition of exogenous rhamnolipids to the mixed
biofilm of S. constellatus 7155 and the P. aeruginosa rhlA mutant
represses S. constellatus 7155 CFU to the same extent as wild-type
P. aeruginosa without tobramycin treatment, effectively comple-
menting the rhlA mutant phenotype (Fig. 6A). Drop collapse as-
says on the supernatants from these biofilms revealed that 50
g/ml exogenous rhamnolipids is comparable to the amount of
surfactant produced by mixed biofilms of S. constellatus 7155 and
P. aeruginosa (Fig. 6B). The addition of exogenous rhamnolipids
did not impact P. aeruginosa viability (Fig. 6C) or cytotoxicity
toward host cells (Fig. 6D). Taken together, our studies are con-
sistent with the model that rhamnolipids produced by P.
aeruginosa, or added exogenously, can reduce S. constellatus 7155
viability.
Rhamnolipids likely inhibit S. constellatus 7155 in mixed
biofilms by direct killing. Rhamnolipids can disrupt biofilms by
directly killing bacteria (42) and/or stimulating dispersion (41,
43). To test the hypothesis that rhamnolipids were dispersing S.
constellatus 7155 biofilms, we measured the amount of S. constel-
latus 7155 in the planktonic fraction of the mixed biofilms
formed on airway cells. In mixed biofilms of S. constellatus 7155
and wild-type P. aeruginosa or the P. aeruginosa rhlA mutant, we
found no evidence of increased dispersion in mixed biofilms that
produced rhamnolipids (S. constellatus 7155 and wild-type P.
aeruginosa) compared to those that did not (S. constellatus 7155
and the P. aeruginosa rhlA mutant), as measured by viable S. con-
stellatus 7155 levels in the planktonic fraction of CF airway
cell-grown biofilms (Fig. 7A). Interestingly, we saw no statisti-
cally significant impact of the rhlA mutant on the viability of
planktonic S. constellatus 7155, consistent with the data in Fig.
2B, indicating that the rhamnolipid-mediated reduction in the
viability of S. constellatus 7155 by P. aeruginosa PA14 may be a
biofilm-specific effect.
To test whether S. constellatus 7155 grown in a biofilm on CF
airway cells was susceptible to direct killing by rhamnolipids, 50
g/ml rhamnolipids was added to preformed single S. constellatus
7155 biofilms grown on CF airway cells. Adding rhamnolipids to
single S. constellatus 7155 biofilms significantly reduced the viabil-
ity of S. constellatus 7155 by 27-fold after 15 h of treatment of
FIG 5 Monorhamnolipids reduce S. constellatus biofilm viability in mixed
culture with P. aeruginosa on CF airway cells. (A) Viability of S. constellatus
7155 grown as mixed biofilms on CF airway cells with the wild type or the rhlA,
rhlB, or rhlC mutant of P. aeruginosa not treated with tobramycin or treated
with 5 g/ml tobramycin. (B) Surfactant score from assays of mixed biofilms
of S. constellatus 7155 with the wild type or the rhlA, rhlB, or rhlC mutant of P.
aeruginosa on CF airway cells not treated with tobramycin or treated with 5
g/ml tobramycin. The dashed line indicates the limit of detection. (C) Via-
bility of the wild type or the rhlA, rhlB, or rhlC mutant of P. aeruginosa grown
as mixed biofilms on CF airway cells with S. constellatus 7155 not treated with
tobramycin or treated with 5 g/ml tobramycin. For all panels, the bars and
error bars indicate the means and SD of the results from three biological rep-
licates. *, P  0.05; **, P  0.01, as determined by an unpaired t test.
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biofilm-grown bacteria (Fig. 7B). Addition of rhamnolipids to the
initial inoculum of a planktonically grown S. constellatus 7155
culture in THY resulted in an approximately 83,000-fold reduc-
tion in recovered CFU after 15 h of incubation (Fig. 7C). The
kinetics of rhamnolipid-mediated killing is relatively rapid, with a
decrease in the viability of S. constellatus 7155 planktonically
grown cells noted as early as 3 h after the addition of surfactant and
an 8,200-fold reduction by 6 h postaddition (Fig. 7D). Thus, the
concentration of rhamnolipids produced by P. aeruginosa in broth
culture (41) and in a mixed biofilm with S. constellatus 7155 on CF
airway cells (Fig. 6B) is sufficient to significantly reduce the via-
bility of S. constellatus 7155 grown as a biofilm on CF airway cells.
FIG 6 Exogeneous rhamnolipids reduce S. constellatus viability in biofilms on CF airway cells. (A and B) Shown are the viability (A) and surfactant scores (B) of
S. constellatus 7155 grown as single and mixed biofilms on CF airway cells with the wild type or the rhlA mutant of P. aeruginosa treated with 50 g/ml
rhamnolipids, as indicated. The dashed line indicates the limit of detection. (C) Viability of the wild type or the rhlA mutant P. aeruginosa grown as mixed biofilms
on CF airway cells with S. constellatus 7155 treated with 50 g/ml rhamnolipids, as indicated. (D) Cytotoxicity of indicated mixed biofilms on CF airway cells.
Cytotoxicity was normalized to total cell lysis. For all panels, the bars and error bars indicate the means and SD of the results from three biological replicates. *,
P  0.05; **, P  0.01, as determined by an unpaired t test.
FIG 7 Rhamnolipids directly kill S. constellatus. (A) Viability of the planktonic fraction of S. constellatus 7155 single and mixed biofilms with the wild type or the
rhlA mutant of P. aeruginosa PA14 on CF airway cells not treated with tobramycin or treated with 5 g/ml tobramycin. (B) Viability of S. constellatus 7155 grown
as single biofilms on CF airway cells treated or not treated with 50 g/ml rhamnolipids, as indicated. *, P value  0.05, as determined by Mann Whitney test. (C)
Viability of S. constellatus grown planktonically overnight in THY medium treated or not treated with 50 g/ml rhamnolipids, as indicated. *, P value  0.05, as
determined by an unpaired t test. (D) Viability of planktonic S. constellatus 7155 incubated in phosphate-buffered saline (PBS) with or without 50 g/ml
rhamnolipids, as indicated. *, P value  0.05, as determined by one-way ANOVA, followed by Tukey’s posttest for multiple comparisons. The bars (A to C) and
data points (D) indicate the means and the error bars indicate the SD of the results from three biological replicates.
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DISCUSSION
Here, we have shown an example of an interspecies interaction
between two predominant organisms in the CF airway, P. aerugi-
nosa and S. constellatus, potentiated by tobramycin, the frontline
maintenance therapy antibiotic used to combat pulmonary infec-
tions in individuals with CF. We found that physiologically rele-
vant concentrations (41) of P. aeruginosa-produced rhamnolipids
can directly kill S. constellatus biofilms formed on CF airway cells,
and our genetic studies suggest that monorhamnolipid produc-
tion is sufficient for this effect. Furthermore, tobramycin treat-
ment reduced the amount of rhamnolipids produced by P. aerugi-
nosa, thus allowing enhanced growth of S. constellatus in mixed
biofilms with P. aeruginosa on plastic and CF airway cells.
It is important to note that the interaction we observed here is
specific to a biofilm of S. constellatus 7155 and P. aeruginosa PA14.
We tested other Streptococcus strains and other isolates of P.
aeruginosa but did not observe a similar interaction. At this stage,
the basis of this specificity is not understood, but it might result,
for example, from the differential production of rhamnolipids by
P. aeruginosa or from S. constellatus 7155 being particularly sensi-
tive to this surfactant. Despite the strain specificity of the infec-
tion, this work does illustrate the potential of microbial interac-
tions in the context of host cells to impact antibiotic tolerance in
unanticipated ways. It will be of interest if other similar interac-
tions are revealed in the future.
Rhamnolipid production in the lung is varied (44); P. aerugi-
nosa strains defective in quorum sensing have been isolated from
the lungs of CF patients (45). These isolates would presumably
reduce the production of rhamnolipids, thereby diminishing a
potentially protective response against S. constellatus in vivo.
However, Duan and colleagues (14) reported that autoiducer-2
produced by a clinical isolate of Streptococcus from an individual
with CF could activate P. aeruginosa genes, including those re-
quired for rhamnolipid production (14). This result suggests that
the presence of Streptococcus may increase the production of rh-
amnolipids in vivo, increasing a potentially protective response
against S. constellatus unless tobramycin is also administered,
which we predict would mitigate rhamnolipid-dependent killing.
Thus, the regulation of rhamnolipid production in the lung is
complex, and further study is warranted to understand the local
and global concentrations of rhamnolipids in particular microbial
communities in individual patients.
Interactions among P. aeruginosa and other members of the CF
microbial community have been described in vitro and in vivo (14,
15, 46–48). P. aeruginosa has been shown to utilize S. aureus as an
iron source, contributing to S. aureus lysis in mixed culture (46).
Further, P. aeruginosa can sense and respond to peptidoglycan
shed from Gram-positive bacteria (47). A recent study of volatile
metabolites collected from breath samples of individuals with CF
suggests that P. aeruginosa produces phenazines, small secreted
molecules that can serve as alternative electron acceptors (49) in
response to 2,3-butanedione (48). The authors hypothesize that
2,3-butanedione is produced by the S. milleri group, of which S.
constellatus is a member, supporting the hypothesis that P. aerugi-
nosa and S. constellatus may interact in vivo in the context of CF.
Riedele and Reichl (15) reported differential effects of the
-lactam antibiotic ceftazidime on broth-grown single and mixed
cultures of the CF pathogens P. aeruginosa, B. cepacia, and S. au-
reus; furthermore, S. aureus was protected from ceftazidime treat-
ment in mixed culture. Coupled with the data presented here, the
unintended consequence of increasing the viability of a pathogen
after antibiotic treatment in mixed culture (with examples using
two different classes of antibiotics) underscores the importance of
studying the effects of antibiotics in the context of a polymicrobial
infection.
In this work, we demonstrate a complex interspecies relation-
ship in a simple two-member community and reveal the molecu-
lar mechanism of at least one aspect of the interaction. While the
work presented here focuses on one specific interaction, as we
better understand how polymicrobial interactions might impact
antibiotic tolerance, such findings might impact approaches to
clinical care. And while identifying and understanding the net-
work of interactions among CF microbes that contribute to dis-
ease with and without antibiotic perturbation are significant
challenges, employing emerging CF sputum microbiomic, metag-
enomic, transcriptomic, and metabolomic studies as a guide to
inform hypotheses, we may be able to leverage our expanded
model system to discover interspecies interactions and their mo-
lecular mechanisms. We suggest that understanding these mech-
anisms may allow us to better predict how a given sputum com-
munity will respond to current antibiotics and may expose
opportunities for novel therapeutic interventions. Ultimately, it
may be possible to use this model system as a platform to select the
best antibiotic(s) for a given microbial community, personalizing
treatment plans based on microbial composition in the lungs.
ACKNOWLEDGMENTS
This work was supported by National Institutes of Health grants R01 2
R37 AI83256-06 and P20 GM103413-10 to G.A.O., the Cystic Fibrosis
Foundation Carol Basbaum Memorial Postdoctoral Fellowship
PRICE13F0 to K.E.P., and a Cystic Fibrosis Foundation Research Devel-
opment Grant (STANTO07R0).
We thank Russell Monds for constructing the phoB mutant used in
this study.
FUNDING INFORMATION
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
provided funding to George A. O’Toole under grant number R37
AI83256. HHS | NIH | National Institute of General Medical Sciences
(NIGMS) provided funding to George A. O’Toole under grant number
GM103413-10. Cystic Fibrosis Foundation (CFF) provided funding to
Katherine E. Price under grant number PRICE13F0. Cystic Fibrosis Foun-
dation (CFF) provided funding under grant number STANTO07R0.
REFERENCES
1. Costerton JW. 2001. Cystic fibrosis pathogenesis and the role of biofilms
in persistent infection. Trends Microbiol 9:50 –52. http://dx.doi.org/10
.1016/S0966-842X(00)01918-1.
2. Heijerman H. 2005. Infection and inflammation in cystic fibrosis: a short
review. J Cyst Fibros 4(Suppl 2):S3–S5.
3. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with
cystic fibrosis. Clin Microbiol Rev 15:194 –222. http://dx.doi.org/10.1128
/CMR.15.2.194-222.2002.
4. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF,
Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ.
2012. Decade-long bacterial community dynamics in cystic fibrosis air-
ways. Proc Natl Acad Sci U S A 109:5809 –5814. http://dx.doi.org/10.1073
/pnas.1120577109.
5. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM,
Wolfgang MC. 2012. The adult cystic fibrosis airway microbiota is stable
over time and infection type, and highly resilient to antibiotic treatment
of exacerbations. PLoS One 7:e45001. http://dx.doi.org/10.1371/journal
.pone.0045001.
6. Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin
Interactions between CF-Relevant Microbes
January 2016 Volume 198 Number 2 jb.asm.org 245Journal of Bacteriology
ML, Morrison HG, Paster BJ, O’Toole GA. 2012. Prevalence of strepto-
cocci and increased polymicrobial diversity associated with cystic fibrosis
patient stability. J Bacteriol 194:4709 – 4717. http://dx.doi.org/10.1128/JB
.00566-12.
7. Lim YW, Schmieder R, Haynes M, Willner D, Furlan M, Youle M,
Abbott K, Edwards R, Evangelista J, Conrad D, Rohwer F. 2013.
Metagenomics and metatranscriptomics: windows on CF-associated viral
and microbial communities. J Cyst Fibros 12:154 –164. http://dx.doi.org
/10.1016/j.jcf.2012.07.009.
8. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS,
Carroll MP, Hoffman L, Daniels TW, Patel N, Forbes B, Bruce KD.
2012. Long-term cultivation-independent microbial diversity analysis
demonstrates that bacterial communities infecting the adult cystic fibrosis
lung show stability and resilience. Thorax 67:867– 873. http://dx.doi.org
/10.1136/thoraxjnl-2011-200932.
9. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison
HG, Sogin ML, O’Toole GA. 2013. Unique microbial communities per-
sist in individual cystic fibrosis patients throughout a clinical exacerba-
tion. Microbiome 1:27. http://dx.doi.org/10.1186/2049-2618-1-27.
10. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens
MJ, Accurso FJ, Laguna TA. 2013. Inflammation and airway microbiota
during cystic fibrosis pulmonary exacerbations. PLoS One 8:e62917. http:
//dx.doi.org/10.1371/journal.pone.0062917.
11. Sibley CD, Grinwis ME, Field TR, Parkins MD, Norgaard JC, Gregson
DB, Rabin HR, Surette MG. 2010. McKay agar enables routine quanti-
fication of the ’Streptococcus milleri’ group in cystic fibrosis patients. J Med
Microbiol 59:534 –540. http://dx.doi.org/10.1099/jmm.0.016592-0.
12. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG.
2008. A polymicrobial perspective of pulmonary infections exposes an
enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A
105:15070 –15075. http://dx.doi.org/10.1073/pnas.0804326105.
13. Field TR, Sibley CD, Parkins MD, Rabin HR, Surette MG. 2010. The
genus Prevotella in cystic fibrosis airways. Anaerobe 16:337–344. http://dx
.doi.org/10.1016/j.anaerobe.2010.04.002.
14. Duan K, Dammel C, Stein J, Rabin H, Surette MG. 2003. Modulation of
Pseudomonas aeruginosa gene expression by host microflora through in-
terspecies communication. Mol Microbiol 50:1477–1491. http://dx.doi
.org/10.1046/j.1365-2958.2003.03803.x.
15. Riedele C, Reichl U. 2011. Interspecies effects in a ceftazidime-treated
mixed culture of Pseudomonas aeruginosa, Burkholderia cepacia and
Staphylococcus aureus: analysis at the single-species level. J Antimicrob
Chemother 66:138 –145. http://dx.doi.org/10.1093/jac/dkq394.
16. Hibbing ME, Fuqua C, Parsek MR, Peterson SB. 2010. Bacterial com-
petition: surviving and thriving in the microbial jungle. Nat Rev Microbiol
8:15–25. http://dx.doi.org/10.1038/nrmicro2259.
17. Stacy A, Everett J, Jorth P, Trivedi U, Rumbaugh KP, Whiteley M. 2014.
Bacterial fight-and-flight responses enhance virulence in a polymicrobial
infection. Proc Natl Acad Sci U S A 111:7819 –7824. http://dx.doi.org/10
.1073/pnas.1400586111.
18. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath
SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G, Elborn JS,
Wolfgang MC. 2011. Use of culture and molecular analysis to determine
the effect of antibiotic treatment on microbial community diversity and
abundance during exacerbation in patients with cystic fibrosis. Thorax
66:579 –584. http://dx.doi.org/10.1136/thx.2010.137281.
19. Parkins MD, Sibley CD, Surette MG, Rabin HR. 2008. The Streptococcus
milleri group–an unrecognized cause of disease in cystic fibrosis: a case
series and literature review. Pediatr Pulmonol 43:490 – 497. http://dx.doi
.org/10.1002/ppul.20809.
20. Anderson GG, Moreau-Marquis S, Stanton BA, O’Toole GA. 2008. In
vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on
cystic fibrosis-derived airway epithelial cells. Infect Immun 76:1423–1433.
http://dx.doi.org/10.1128/IAI.01373-07.
21. Filkins LM, Graber JA, Olson DG, Dolben EL, Lynd LR, Bhuju S,
O’Toole GA. 2015. Coculture of Staphylococcus aureus with Pseudomonas
aeruginosa drives S. aureus towards fermentative metabolism and reduced
viability in a cystic fibrosis model. J Bacteriol 197:2252–2264. http://dx.doi
.org/10.1128/JB.00059-15.
22. Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A,
Ye S, O’Toole GA, Stanton BA. 2008. The DeltaF508-CFTR mutation
results in increased biofilm formation by Pseudomonas aeruginosa by in-
creasing iron availability. Am J Physiol Lung Cell Mol Physiol 295:L25–
L37. http://dx.doi.org/10.1152/ajplung.00391.2007.
23. Hentchel-Franks K, Lozano D, Eubanks-Tarn V, Cobb B, Fan L, Oster
R, Sorscher E, Clancy JP. 2004. Activation of airway Cl secretion in
human subjects by adenosine. Am J Respir Cell Mol Biol 31:140 –146.
http://dx.doi.org/10.1165/rcmb.2004-0012OC.
24. Bruscia E, Sangiuolo F, Sinibaldi P, Goncz KK, Novelli G, Gruenert DC.
2002. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by
SFHR-mediated targeting. Gene Ther 9:683– 685. http://dx.doi.org/10
.1038/sj.gt.3301741.
25. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, Fink-
beiner WE, Widdicombe JH, Gruenert DC. 1994. CFTR expression and
chloride secretion in polarized immortal human bronchial epithelial cells.
Am J Respir Cell Mol Biol 10:38 – 47. http://dx.doi.org/10.1165/ajrcmb.10
.1.7507342.
26. Bloemberg GV, O’Toole GA, Lugtenberg BJ, Kolter R. 1997. Green
fluorescent protein as a marker for Pseudomonas spp. Appl Environ Mi-
crobiol 63:4543– 4551.
27. Deziel E, Comeau Y, Villemur R. 2001. Initiation of biofilm formation by
Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated
and highly adherent phenotypic variants deficient in swimming, swarm-
ing, and twitching motilities. J Bacteriol 183:1195–1204. http://dx.doi.org
/10.1128/JB.183.4.1195-1204.2001.
28. Caiazza NC, Shanks RM, O’Toole GA. 2005. Rhamnolipids modulate
swarming motility patterns of Pseudomonas aeruginosa. J Bacteriol 187:
7351–7361. http://dx.doi.org/10.1128/JB.187.21.7351-7361.2005.
29. Mason DJ, Shanmuganathan S, Mortimer FC, Gant VA. 1998. A fluo-
rescent Gram stain for flow cytometry and epifluorescence microscopy.
Appl Environ Microbiol 64:2681–2685.
30. Hoffman LR, D’Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller
SI. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation.
Nature 436:1171–1175. http://dx.doi.org/10.1038/nature03912.
31. Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM,
Lory S, Greenberg EP. 2001. Gene expression in Pseudomonas aeruginosa
biofilms. Nature 413:860 – 864. http://dx.doi.org/10.1038/35101627.
32. Marr AK, Gooderham WJ, Hancock RE. 2006. Antibacterial peptides for
therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol
6:468 – 472. http://dx.doi.org/10.1016/j.coph.2006.04.006.
33. Linares JF, Gustafsson I, Baquero F, Martinez JL. 2006. Antibiotics as
intermicrobial signaling agents instead of weapons. Proc Natl Acad Sci
U S A 103:19484 –19489. http://dx.doi.org/10.1073/pnas.0608949103.
34. Kindrachuk KN, Fernández L, Bains M, Hancock RE. 2011. Involve-
ment of an ATP-dependent protease, PA0779/AsrA, in inducing heat
shock in response to tobramycin in Pseudomonas aeruginosa. Antimi-
crob Agents Chemother 55:1874 –1882. http://dx.doi.org/10.1128/AAC
.00935-10.
35. Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA,
Hougen HP, Calum H, Madsen KG, Moser C, Molin S, Hoiby N,
Givskov M. 2005. Pseudomonas aeruginosa tolerance to tobramycin, hy-
drogen peroxide and polymorphonuclear leukocytes is quorum-sensing
dependent. Microbiology 151:373–383. http://dx.doi.org/10.1099/mic.0
.27463-0.
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